FATE THERAPEUTICS INC (FATE)

Company Profile

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 551 full-time employees. The company went IPO on 2013-10-01. The firm is focused on developing a pipeline of programmed cellular immunotherapies for patients with cancer and autoimmune disorders. The company uses human induced pluripotent stem cells (iPSCs) generated from its iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The firm is advancing a pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted natural killer (NK) and T-cell product candidates. The firm's product pipeline includes FT576, FT819, FT825 and FT522. Its FT576, is an iPSC-derived, B-cell maturation antigen (BCMA)-targeted CAR NK cell product candidate for the treatment of multiple myeloma. Its FT819, is an iPSC-derived CAR T-cell therapy candidate, which is in Phase I study for the treatment of adult patients with relapsed / refractory B-cell malignancies, including B-cell lymphoma and chronic lymphocytic leukemia.

Company Info

FATE THERAPEUTICS INC

12278 Scripps Summit Drive

San Diego CALIFORNIA 92121

P: 18588751803

CEO: J. Scott Wolchko

Employees: 551

Website: https://fatetherapeutics.com/